Barasertib-HQPA (Synonyms: AZD2811; INH-34; AZD1152-HQPA)

Name: Barasertib-HQPA
Brand: MedChemExpress
SKU: HY-10126
Rating: 5.0 (9 reviews)

Cat. No.: HY-10126 Purity: 98.90%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.

For research use only. We do not sell to patients.

CAS No. : 722544-51-6

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Barasertib-HQPA:

Barasertib In-stock
Barasertib-HQPA (Standard) Get quote

9 Publications Citing Use of MCE Barasertib-HQPA

Cell Imaging/Staining

Cell Proliferation/Viability Assay

: Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: J Cell Sci. 2025 Sep 1:jcs.263766. [Abstract]; Confocal images of microtubule dynamics in control extracts (top row) and extracts with 40 µM Aurora kinase B inhibitor Barasertib-HQPA (bottom row). n=6. Each image is a maximum-intensity projection of nine confocal planes spanning 16 µm of depth. Imaging started at an arbitrary time point when asters had just begun to form in the untreated extracts. The results showed that Aurora kinase B inhibition by Barasertib-HQPA abolishes the aster, and the cell-like compartments form with a substantial delay.

: Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Jan 11;23(2):763.; MCD4 were left untreated or treated with DMSO (0.3% or 0.2%, 1 h), Alisertib (AURKA inhibitor; 30 µM or 20 µM, 1 h), or Barasertib-HQPA (AURKB inhibitor; 30 µM or 20 µM, 1 h) alone or in combination with forskolin (Fsk; 30 µM, 30 min) or arginine-vasopressin (AVP; 100 nM, 30 min) where indicated. AQP2 was detected by immunofluorescence microscopy. Shown are representative images of four independent experiments; scale bar 30 µm. AQP2 was quantified using a segmentation-based approach. Ratios > 1 indicate a predominant localization at the plasma membrane.

: Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2021 Sep 1;406(1):112741. [Abstract]; The IC₅₀ of AURKB inhibitors (AZD1152-HQPA (Barasertib-HQPA, 48 h) and hesperadin) was explored by CCK-8 in gastric cancer cells (MGC-803 and SGC-7901).

: Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Ann Transl Med. 2020 May;8(10):646. [Abstract]; The effect of AURKB inhibitor (AZD1152 (Barasertib)-HQPZ (10 μM; 48 h) and hesperidin) on Caki-1 and 786-0 cells with ALKBH5 overexpression was measured by CCK8 and clone formation assays. The colony fold (NC/ALKBH5) is stated under the histogram.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aurora Kinase Isoform Specific Products:

View All Isoforms

Aurora Kinase Aurora A Aurora B Aurora C

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Aurora B

0.37 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.1 μM Compound: AAZD1152-HQPA	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 25036791]
A549	IC₅₀	5.4 μM Compound: AAZD1152-HQPA	Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay	[PMID: 25036791]
A549	IC₅₀	8.3 μM Compound: AAZD1152-HQPA	Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay	[PMID: 25036791]
HL-60	IC₅₀	12.7 nM Compound: AZD1152	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
HepG2	IC₅₀	0.1 μM Compound: AAZD1152-HQPA	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 25036791]
MOLM-13	IC₅₀	1 nM Compound: AZD1152-HQPA	Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days	[PMID: 17495131]
MOLM-13	IC₅₀	12 nM Compound: AZD1152-HQPA	Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay	[PMID: 17495131]
MOLM-13	IC₅₀	9.7 nM Compound: AZD1152	Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
MV4-11	IC₅₀	2.8 nM Compound: AZD1152-HQPA	Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days	[PMID: 17495131]
MV4-11	IC₅₀	8 nM Compound: AZD1152-HQPA	Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay	[PMID: 17495131]
MV4-11	IC₅₀	8.6 nM Compound: AZD1152	Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
SW-620	IC₅₀	0.017 μM Compound: 7, AZD-1152 HQPA	Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation	[PMID: 19320489]
THP-1	IC₅₀	25.1 nM Compound: AZD1152	Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]

In Vitro

Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells^[1].
Barasertib-hydroxyquinazoline pyrazol anilide (HQPA) is converted rapidly to the active Barasertib-HQPA in plasma^[2].
Barasertib-HQPA treatment induced defective cell survival, polyploidy, and cell death in LNCaP cell line^[3].
Barasertib-HQPA induces a marked anti-propliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1].

Cell Line:	AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells.
Concentration:	0-100 nM. (Barasertib -HQPA)
Incubation Time:	48 h.
Result:	IC₅₀ values ranged from 3 nM to 40 nM.

In Vivo

Barasertib-HQPA (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors^[1].
Barasertib-HQPA (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts^[1].
Barasertib-HQPA (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to z100%; P < 0.05) in immunodeficient mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

507.56

Formula

C₂₆H₃₀FN₇O₃

CAS No.

722544-51-6

Appearance

Solid

Color

White to yellow

SMILES

O=C(CC1=NNC(NC2=C3C=CC(OCCCN(CCO)CC)=CC3=NC=N2)=C1)NC4=CC=CC(F)=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 22 mg/mL (43.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9702 mL	9.8511 mL	19.7021 mL
5 mM	0.3940 mL	1.9702 mL	3.9404 mL
10 mM	0.1970 mL	0.9851 mL	1.9702 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.90%

Select Batch:

Data Sheet (275 KB) SDS (396 KB)

COA (246 KB) HNMR (283 KB) RP-HPLC (263 KB) MS (68 KB) Elemental Analysis Report (103 KB)

Handling Instructions (2659 KB)

References

[1]. Yang, Jing., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep 15;110(6):2034-40. [Content Brief]

[2]. Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13(12):3682-8. [Content Brief]

[3]. Zekri A, et al. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumour Biol. 2015 Feb;36(2):623-32. [Content Brief]

[4]. Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69(10):4150-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9702 mL	9.8511 mL	19.7021 mL	49.2553 mL
	5 mM	0.3940 mL	1.9702 mL	3.9404 mL	9.8511 mL
	10 mM	0.1970 mL	0.9851 mL	1.9702 mL	4.9255 mL
	15 mM	0.1313 mL	0.6567 mL	1.3135 mL	3.2837 mL
	20 mM	0.0985 mL	0.4926 mL	0.9851 mL	2.4628 mL
	25 mM	0.0788 mL	0.3940 mL	0.7881 mL	1.9702 mL
	30 mM	0.0657 mL	0.3284 mL	0.6567 mL	1.6418 mL
	40 mM	0.0493 mL	0.2463 mL	0.4926 mL	1.2314 mL

Barasertib-HQPA Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Barasertib-HQPA (Synonyms: AZD2811; INH-34; AZD1152-HQPA)

Customer Review

Other Forms of Barasertib-HQPA:

Barasertib-HQPA Related Antibodies

9 Publications Citing Use of MCE Barasertib-HQPA

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aurora Kinase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Barasertib-HQPA Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Barasertib-HQPA Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report